BTAI
HEALTHCAREBioXcel Therapeutics Inc
$1.30+0.05 (+4.00%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BTAI Today?
No stock-specific AI insight has been generated for BTAI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.01$8.08
$1.30
Fundamentals
Market Cap$35M
P/E Ratio—
EPS$-5.64
Dividend Yield—
Dividend / Share—
ROE-17.7%
Profit Margin—
Debt / Equity—
Trading
Volume908K
Avg Volume (10D)—
Shares Outstanding27.1M
BTAI News
20 articles- Verastem (VSTM) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?Yahoo Finance·May 4, 2026
- H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure ConcernsYahoo Finance·Apr 17, 2026
- BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home SettingYahoo Finance·Apr 17, 2026
- How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution RisksYahoo Finance·Apr 13, 2026
- BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress ReactionsYahoo Finance·Apr 8, 2026
- BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home SettingYahoo Finance·Apr 1, 2026
- How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution RisksYahoo Finance·Mar 29, 2026
- BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient SettingYahoo Finance·Mar 27, 2026
- How The BioXcel Therapeutics (BTAI) Story Is Shifting With Dilution Risks And Funding NeedsYahoo Finance·Mar 12, 2026
- BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct OfferingYahoo Finance·Mar 11, 2026
- BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct OfferingYahoo Finance·Mar 10, 2026
- BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid WithdrawalYahoo Finance·Mar 5, 2026
- BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s DementiaYahoo Finance·Feb 19, 2026
- BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home SettingYahoo Finance·Feb 12, 2026
- Rigel Appoints Michael P. Miller to the Board of DirectorsYahoo Finance·Feb 3, 2026
- BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home SettingYahoo Finance·Jan 20, 2026
- 1 Top Penny Stock to Watch NowBarchart·Jan 17, 2026
- BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home SettingYahoo Finance·Jan 12, 2026
- BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®Yahoo Finance·Jan 7, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$1.25
Day High$0.00
Day Low$0.00
52 Week High$8.08
52 Week Low$1.01
52-Week Range
$1.01$8.08
$1.30
Fundamentals
Market Cap$35M
P/E Ratio—
EPS$-5.64
Dividend Yield—
Dividend / Share—
ROE-17.7%
Profit Margin—
Debt / Equity—
Trading
Volume908K
Avg Volume (10D)—
Shares Outstanding27.1M
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—